Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation

被引:169
作者
van Spriel, AB
Leusen, JHW
van Egmond, M
Dijkman, HBPM
Assmann, KJM
Mayadas, TN
van de Winkel, JGJ
机构
[1] Univ Utrecht, Med Ctr, Immunotherapy Lab, NL-3584 EA Utrecht, Netherlands
[2] Univ Utrecht, Med Ctr, Medarex Europe, NL-3584 EA Utrecht, Netherlands
[3] Univ Nijmegen Hosp, Dept Pathol, Nijmegen, Netherlands
[4] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA
关键词
D O I
10.1182/blood.V97.8.2478
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Receptors for human immunoglobulin (Ig)G and IgA initiate potent cytolysis of antibody (Ab)-coated targets by polymorphonuclear leukocytes (PMNs). Mac-1 (complement receptor type 3, CD11b/CD18) has previously been implicated in receptor cooperation with Fc receptors (FcRs). The role of Mac-1 in FcR-mediated lysis of tumor cells was characterized by studying normal human PMNs, Mac-1-deficient mouse PMNs, and mouse PMNs transgenic for human FcR. All PMNs efficiently phagocytosed Ab-coated particles, However, antibody-dependent cellular cytotoxicity (ADCC) was abrogated in Mac-1(-/-) PMNs and in human PMNs blocked with anti-Mac-1 monoclonal Ab (mAb). Mac-1(-/-) PMNs were unable to spread on Ab-opsonized target cells and other Ab-coated surfaces. Confocal laser scanning and electron microscopy revealed a striking difference in immunologic synapse formation between Mac1(-/-) and wild-type PMNs. Also, respiratory burst activity could be measured outside membrane-enclosed compartments by using Mac-1(-/-) PMNs bound to Ab-coated tumor cells, in contrast to wild-type PMNs. In summary, these data document an absolute requirement of Mac-1 for FcR-mediated PMN cytotoxicity toward tumor targets. Mac-1(-/-) PMNs exhibit defective spreading on Ab-coated targets, impaired formation of immunologic synapses, and absent tumor cytolysis. (Blood, 2001;97: 2478-2486) (C) 2001 by The American Society of Hematology.
引用
收藏
页码:2478 / 2486
页数:9
相关论文
共 73 条
[1]   THE SEVERE AND MODERATE PHENOTYPES OF HERITABLE MAC-1, LFA-1 DEFICIENCY - THEIR QUANTITATIVE DEFINITION AND RELATION TO LEUKOCYTE DYSFUNCTION AND CLINICAL-FEATURES [J].
ANDERSON, DC ;
SCHMALSTEIG, FC ;
FINEGOLD, MJ ;
HUGHES, BJ ;
ROTHLEIN, R ;
MILLER, LJ ;
KOHL, S ;
TOSI, MF ;
JACOBS, RL ;
WALDROP, TC ;
GOLDMAN, AS ;
SHEARER, WT ;
SPRINGER, TA .
JOURNAL OF INFECTIOUS DISEASES, 1985, 152 (04) :668-689
[2]   The beta 2 integrin Mac-1 but not p150,95 associates with Fc gamma RIIA [J].
Annenkov, A ;
Ortlepp, S ;
Hogg, N .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (01) :207-212
[3]  
ARNAOUT MA, 1990, BLOOD, V75, P1037
[4]   INHIBITION OF PHAGOCYTOSIS OF COMPLEMENT-C3-COATED OR IMMUNOGLOBULIN-G-COATED PARTICLES AND OF C3BI BINDING BY MONOCLONAL-ANTIBODIES TO A MONOCYTE-GRANULOCYTE MEMBRANE GLYCOPROTEIN (MOL) [J].
ARNAOUT, MA ;
TODD, RF ;
DANA, N ;
MELAMED, J ;
SCHLOSSMAN, SF ;
COLTEN, HR .
JOURNAL OF CLINICAL INVESTIGATION, 1983, 72 (01) :171-179
[5]   LEUKOCYTE ADHESION MOLECULES DEFICIENCY - ITS STRUCTURAL BASIS, PATHOPHYSIOLOGY AND IMPLICATIONS FOR MODULATING THE INFLAMMATORY RESPONSE [J].
ARNAOUT, MA .
IMMUNOLOGICAL REVIEWS, 1990, 114 :145-180
[6]   GENERATION OF SIGNALS ACTIVATING NEUTROPHIL FUNCTIONS BY LEUKOCYTE INTEGRINS - LFA-1 AND GP150/95, BUT NOT CR3, ARE ABLE TO STIMULATE THE RESPIRATORY BURST OF HUMAN NEUTROPHILS [J].
BERTON, G ;
LAUDANNA, C ;
SORIO, C ;
ROSSI, F .
JOURNAL OF CELL BIOLOGY, 1992, 116 (04) :1007-1017
[7]   SUBCELLULAR-LOCALIZATION OF THE B-CYTOCHROME COMPONENT OF THE HUMAN NEUTROPHIL MICROBICIDAL OXIDASE - TRANSLOCATION DURING ACTIVATION [J].
BORREGAARD, N ;
HEIPLE, JM ;
SIMONS, ER ;
CLARK, RA .
JOURNAL OF CELL BIOLOGY, 1983, 97 (01) :52-61
[8]   MECHANISM OF INHIBITION OF IMMUNOGLOBULIN G-MEDIATED PHAGOCYTOSIS BY MONOCLONAL-ANTIBODIES THAT RECOGNIZE THE MAC-1 ANTIGEN [J].
BROWN, EJ ;
BOHNSACK, JF ;
GRESHAM, HD .
JOURNAL OF CLINICAL INVESTIGATION, 1988, 81 (02) :365-375
[9]   COMPLEMENT RECEPTORS AND PHAGOCYTOSIS [J].
BROWN, EJ .
CURRENT OPINION IN IMMUNOLOGY, 1991, 3 (01) :76-82
[10]  
Brown EJ, 1998, IMMUNOL MED, V26, P141